Swiss National Bank Portfolio holdings
The Swiss National Bank (SNB), founded in 1907 and headquartered in Zurich with an office in Bern, is Switzerland’s central bank, responsible for conducting monetary policy, issuing the Swiss franc, and ensuring price stability, while uniquely managing a massive investment portfolio. Unlike most central banks, the SNB is a joint-stock company with shares traded on the SIX Swiss Exchange, owned roughly 55% by public entities like cantons and 45% by private investors, yet it operates independently under federal oversight. It holds over $800 billion in foreign currency reserves as of late 2024—invested in global equities, bonds, and gold—to manage the franc’s value, famously intervening in markets to prevent excessive appreciation, as seen with the 2015 abandonment of the euro peg. Led by Chairman Thomas Jordan until his planned exit in September 2024, the SNB balances its dual role as a monetary authority and a significant global investor, influencing both Swiss and international financial stability.
Top Buys
| 1 |
NVIDIA
NVDA
|
+$757M |
| 2 |
Microsoft
MSFT
|
+$725M |
| 3 |
Apple
AAPL
|
+$628M |
| 4 |
Amazon
AMZN
|
+$487M |
| 5 |
Meta Platforms (Facebook)
META
|
+$355M |
Top Sells
| 1 |
DFS
Discover Financial Services
DFS
|
+$121M |
| 2 |
KE Holdings
BEKE
|
+$31.8M |
| 3 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$24.4M |
| 4 |
X
US Steel
X
|
+$18.4M |
| 5 |
BERY
Berry Global Group, Inc.
BERY
|
+$15.6M |
Sector Composition
| 1 | Technology | 34.97% |
| 2 | Consumer Discretionary | 11.79% |
| 3 | Communication Services | 10.31% |
| 4 | Healthcare | 9.95% |
| 5 | Industrials | 9.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1451
QuidelOrtho
QDEL
$1.94B
| $3.71M | ﹤0.01% |
128,840
-1,500
| -1% | -$43.2K |
|
1452
Teradata
TDC
$2B
| $3.68M | ﹤0.01% |
165,059
-20,300
| -11% | -$453K |
|
1453
ePlus
PLUS
$1.97B
| $3.67M | ﹤0.01% |
50,856
-1,100
| -2% | -$79.3K |
|
1454
FIVE9
FIVN
$2B
| $3.66M | ﹤0.01% |
138,300
-7,500
| -5% | -$199K |
|
1455
Agios Pharmaceuticals
AGIO
$2.14B
| $3.64M | ﹤0.01% |
109,460
+10,000
| +10% | +$333K |
|
1456
John Wiley & Sons Class A
WLY
$2.19B
| $3.63M | ﹤0.01% |
81,400
-1,600
| -2% | -$71.4K |
|
1457
Pitney Bowes
PBI
$1.96B
| $3.63M | ﹤0.01% |
332,300
+14,500
| +5% | +$158K |
|
|
TGI
1458
DELISTED
Triumph Group
TGI
| $3.62M | ﹤0.01% |
140,500
-1,900
| -1% | -$48.9K |
|
1459
ManpowerGroup
MAN
$1.78B
| $3.61M | ﹤0.01% |
89,300
-1,700
| -2% | -$68.7K |
|
1460
Pathward Financial
CASH
$1.72B
| $3.6M | ﹤0.01% |
45,500
-1,200
| -3% | -$94.9K |
|
1461
Symbotic
SYM
$5.32B
| $3.6M | ﹤0.01% |
92,600
+10,200
| +12% | +$396K |
|
1462
CSG Systems International
CSGS
$1.86B
| $3.59M | ﹤0.01% |
55,000
-1,400
| -2% | -$91.4K |
|
1463
UFP Technologies
UFPT
$1.54B
| $3.59M | ﹤0.01% |
14,700
-200
| -1% | -$48.8K |
|
1464
PBF Energy
PBF
$3.18B
| $3.59M | ﹤0.01% |
165,600
-1,600
| -1% | -$34.7K |
|
1465
Mirum Pharmaceuticals
MIRM
$3.73B
| $3.57M | ﹤0.01% |
70,200
+400
| +0.6% | +$20.4K |
|
1466
Mercury Insurance
MCY
$4.4B
| $3.56M | ﹤0.01% |
52,900
-800
| -1% | -$53.9K |
|
1467
Standex International
SXI
$2.47B
| $3.55M | ﹤0.01% |
22,700
-700
| -3% | -$110K |
|
1468
NovoCure
NVCR
$1.36B
| $3.54M | ﹤0.01% |
199,100
| – | – |
|
1469
Bausch Health
BHC
$2.68B
| $3.54M | ﹤0.01% |
533,260
-4,400
| -0.8% | -$29.2K |
|
1470
Kulicke & Soffa
KLIC
$2.01B
| $3.53M | ﹤0.01% |
102,000
-2,400
| -2% | -$83K |
|
1471
American Airlines Group
AAL
$8.52B
| $3.53M | ﹤0.01% |
314,200
-4,100
| -1% | -$46K |
|
1472
PureCycle Technologies
PCT
$2.4B
| $3.52M | ﹤0.01% |
257,100
+4,900
| +2% | +$67.1K |
|
1473
DigitalOcean
DOCN
$3.25B
| $3.52M | ﹤0.01% |
123,100
-2,100
| -2% | -$60K |
|
1474
Denali Therapeutics
DNLI
$2.07B
| $3.51M | ﹤0.01% |
250,900
| – | – |
|
1475
Hawaiian Electric Industries
HE
$2.09B
| $3.5M | ﹤0.01% |
329,600
-4,500
| -1% | -$47.8K |
|